Advertisement


Howard M. Sandler, MD, on RTOG’s Past and NRG’s Future

2016 ASTRO Annual Meeting

Advertisement

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)



Related Videos

Head and Neck Cancer

Takeshi Kodaira, MD, PhD, on Glottic Cancer: Results of a Japan Clinical Oncology Group Study

Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)

Lymphoma

Richard T. Hoppe, MD, on Lymphoma: Improving Outcomes

Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)

Issues in Oncology

Lia M. Halasz, MD, on Disparities in Radiotherapy Delivery

Lia M. Halasz, MD, of the University of Washington Seattle Cancer Care Alliance, summarizes a session on the uneven delivery of radiotherapy in the United States and around the world. (Scientific Session 10)

Bruce D. Minsky, MD's, Meeting Highlights: An Expert Perspective

Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.

Prostate Cancer

Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity

Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)

Advertisement

Advertisement




Advertisement